Opinion|Videos|March 11, 2025
Overcoming Barriers to Narcolepsy Treatment and Looking to the Future
Author(s)R. Robert Auger, MD
An expert discusses considerations for tailoring narcolepsy treatment plans for patients with complex comorbidities or lifestyle needs, the role of insurance policies, prior authorizations, and specialty pharmacies in treatment access, emerging strategies to improve care in underserved populations, and the role of hypocretin in narcolepsy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What considerations should clinicians keep in mind when tailoring treatment plans for patients with narcolepsy, particularly those with complex comorbidities or lifestyle needs?
- What role do insurance policies, prior authorizations, and specialty pharmacies play in treatment access, and how can clinicians effectively navigate these systems?
- What are some emerging strategies or innovations that may improve accessibility to narcolepsy care in underserved populations?
Advertisement
Related to this article
Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
3
Christopher Stanley, M.D., MBA, on culture change and implementing value-based care
4
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
5